{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:40Z","timestamp":1787026600901,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mendelian randomization (MR) was used to evaluate the bidirectional causal relationship between inflammatory bowel disease (IBD) and interleukins (ILs), chemokines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Genetic instruments and summary data of five ILs and six chemokines were obtained from a genome-wide association study database, and instrumental variables related to IBD were obtained from the FinnGen Consortium. Inverse variance weighting (IVW) was used as the main MR analysis method, and several other MR methods including MR-Egger and weighted median were used to confirm the reliability of the results. Sensitivity analyses such as heterogeneity and pleiotropy were also performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The IVW method provided evidence to support that genetically predicted IL-16, IL-18, and CXCL10 significantly positively correlated with IBD, while IL-12p70 and CCL23 significantly negatively correlated with IBD. IL-16 and IL-18 had a suggestive association with an increased risk of ulcerative colitis (UC), and CXCL10 had a suggestive association with an increased risk of Crohn\u2019s disease (CD). However, there was no evidence to support that IBD and two main subtypes (UC and CD) are associated with changes in the levels of ILs and chemokines. The results of the sensitivity analyses were robust and no evidence of heterogeneity and horizontal pleiotropy was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study showed that some ILs and chemokines affect IBD, but IBD and its main subtypes (UC and CD) have no effect on the level changes of ILs and chemokines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1168188","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T08:01:37Z","timestamp":1683619297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Association between inflammatory bowel disease and interleukins, chemokines: a two-sample bidirectional mendelian randomization study"],"prefix":"10.3389","volume":"14","author":[{"given":"Guojiu","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanzhi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.3390\/nu14183745","article-title":"The lactobacillus gasseri G098 strain mitigates symptoms of DSS-induced inflammatory bowel disease in mice","volume":"14","author":"Zhang","year":"2022","journal-title":"Nutrients"},{"key":"B2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.01.028","article-title":"Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century","volume":"18","author":"Ananthakrishnan","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of inflammatory bowel disease: innate immune system","volume":"24","author":"Saez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","article-title":"Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention","volume":"16","author":"Sewell","year":"2022","journal-title":"J Crohns Colitis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-009-0031-z","article-title":"Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients","volume":"57","author":"Szkaradkiewicz","year":"2009","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i16.1912","article-title":"Interleukin-6 compared to the other Th17\/Treg related cytokines in inflammatory bowel disease and colorectal cancer","volume":"26","author":"Velikova","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-016-8804-z","article-title":"Interleukin 27 is up-regulated in patients with active inflammatory bowel disease","volume":"64","author":"Furuzawa Carballeda","year":"2016","journal-title":"Immunol Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15813","article-title":"Mucosal interleukin-8 expression as a predictor of subsequent relapse in ulcerative colitis patients with Mayo endoscopic subscore 0","volume":"37","author":"Uchiyama","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.10.008","article-title":"Chemokine and cytokine levels in inflammatory bowel disease patients","volume":"77","author":"Singh","year":"2016","journal-title":"Cytokine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1159\/000509110","article-title":"Predisposition of inflammatory bowel disease is influenced by IL-8, IL-10, and IL-18 polymorphisms: a meta-analysis","volume":"181","author":"Su","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"109020","DOI":"10.1016\/j.intimp.2022.109020","article-title":"Mendelian randomization study for the roles of IL-18 and IL-1 receptor antagonist in the development of inflammatory bowel disease","volume":"110","author":"Mi","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.919973","article-title":"Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment","volume":"13","author":"Ihim","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2006.26.511","article-title":"Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases","volume":"26","author":"Glass","year":"2006","journal-title":"J Interferon Cytokine Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-013-1425-y","article-title":"IL-18 in inflammatory and autoimmune disease","volume":"70","author":"Sedimbi","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.11.6829","article-title":"IL-18, a novel immunoregulatory cytokine, is up-regulated in crohn's disease: expression and localization in intestinal mucosal cells","volume":"162","author":"Pizarro","year":"1999","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01091","article-title":"IL-33 and IL-18 in inflammatory bowel disease etiology and microbial interactions","volume":"10","author":"Williams","year":"2019","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.3.326","article-title":"Increased expression of IL-16 in inflammatory bowel disease","volume":"48","author":"Seegert","year":"2001","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202598","article-title":"IL-16 induces intestinal inflammation via PepT1 upregulation in a pufferfish model: new insights into the molecular mechanism of inflammatory bowel disease","volume":"191","author":"Wang","year":"2013","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6690","DOI":"10.1038\/s41598-021-86251-w","article-title":"Serum biomarkers confirming stable remission in inflammatory bowel disease","volume":"11","author":"Kessel","year":"2021","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/01.MIB.0000178263.34099.89","article-title":"Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice","volume":"11","author":"Hyun","year":"2005","journal-title":"Inflammation Bowel Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx145","article-title":"Chemokines and chemokine receptors as therapeutic targets in inflammatory bowel disease; pitfalls and promise","volume":"12","author":"Trivedi","year":"2018","journal-title":"J Crohns Colitis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5A0717-302","article-title":"A novel function of CXCL10 in mediating monocyte production of proinflammatory cytokines","volume":"102","author":"Zhao","year":"2017","journal-title":"J Leukoc Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/01.MIB.0000194183.92671.b6","article-title":"Both IL-12p70 and IL-23 are synthesized during active crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody","volume":"12","author":"Fuss","year":"2006","journal-title":"Inflammation Bowel Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgn281","article-title":"The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer","volume":"30","author":"Gao","year":"2009","journal-title":"Carcinogenesis"},{"key":"B27","article-title":"Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation","volume":"9","author":"Naftali","year":"2007","journal-title":"Isr Med Assoc J"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.154.5.2434","article-title":"Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. a novel mechanism of chronic intestinal inflammation","volume":"154","author":"Casini-Raggi","year":"1995","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-022-07397-y","article-title":"Gene expression analysis of intestinal IL-8, IL-17 a and IL-10 in patients with celiac and inflammatory bowel diseases","volume":"49","author":"Aghamohamadi","year":"2022","journal-title":"Mol Biol Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1159\/000507931","article-title":"Activation, deficiency, and reduced IFN-gamma production of mucosal-associated invariant T cells in patients with inflammatory bowel disease","volume":"12","author":"Ju","year":"2020","journal-title":"J Innate Immun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.12.004","article-title":"Chemokines and chemokine receptors in inflammatory bowel disease: recent findings and future perspectives","volume":"27","author":"Camba-Gomez","year":"2022","journal-title":"Drug Discov Today"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1168188\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T08:01:44Z","timestamp":1683619304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1168188\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2023.1168188"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1168188","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"article-number":"1168188"}}